Drug Profile
MUC1 infected dendritic cells induced cytotoxic T lymphocyte therapy - Beijing Doing Biomedical
Latest Information Update: 06 Sep 2023
Price :
$50
*
At a glance
- Originator Beijing Doing Biomedical
- Class Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Gastric cancer
Most Recent Events
- 06 Sep 2023 Discontinued - Preclinical for Gastric cancer (Late-stage disease) in China (IV)
- 28 Jul 2019 No recent reports of development identified for preclinical development in Gastric-cancer(Late-stage disease) in China (IV, Infusion)
- 01 Jun 2015 Preclinical trials in Gastric cancer (Late-stage disease) in China (IV)